{"nctId":"NCT01587989","briefTitle":"A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate","startDateStruct":{"date":"2012-02"},"conditions":["Rheumatoid Arthritis"],"count":77,"armGroups":[{"label":"A Methotrexate","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: methotrexate","Drug: tocilizumab [RoActemra/Actemra]"]},{"label":"B Methotrexate Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: methotrexate","Drug: placebo","Drug: tocilizumab [RoActemra/Actemra]"]}],"interventions":[{"name":"methotrexate","otherNames":[]},{"name":"methotrexate","otherNames":[]},{"name":"placebo","otherNames":[]},{"name":"tocilizumab [RoActemra/Actemra]","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult patients, \\>/= 18 years of age\n* Rheumatoid arthritis of \\>/= 1 year duration\n* Mild to moderate disease activity at screening (DAS 28 \\</= 4.5 and \\>2.6)\n* On methotrexate treatment for at least 12 weeks, at stable oral dose of (10)15 mg to 25 mg/week for at least 6 weeks prior to Day 1\n* Body weight \\</= 150 kg\n* Oral corticosteroids must have been at stable dose (maximum 10 mg/day) for at least 25 out of 28 days prior to baseline\n\nExclusion Criteria:\n\n* Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months after baseline\n* Rheumatic autoimmune disease other than rheumatoid arthritis\n* Functional class IV American College of Rheumatology (ACR) Classification\n* Prior history of or current inflammatory joint disease other than rheumatoid arthritis\n* Treatment with a biologic agent at any time prior to baseline\n* Treatment with traditional DMARDs other than methotrexate within 1 month (for leflunomide 3 months) prior to baseline\n* Intraarticular or parenteral corticosteroids within 6 weeks prior to baseline\n* Previous treatment with tocilizumab\n* Pregnant or lactating women\n* Uncontrolled disease states, such as asthma, psoriasis or inflammatory bowel disease where flares are commonly treated with oral or parenteral corticosteroids\n* Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections\n* History of or currently active primary or secondary immunodeficiency\n* Evidence of active malignant disease, malignancies diagnosed within the previous 5 years\n* Active tuberculosis requiring treatment within the previous 3 years\n* Positive for HIV infection","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Week 12 (Randomization) to Week 24 in DAS28","description":"The DAS28 is a combined index for measuring disease activity in rheumatoid arthritis (RA). The index includes swollen joint counts (SJC) and tender joint counts (TJC), both scored 0-28 (higher scores indicate higher disease activity), as well as acute phase response (APR) determined as erythrocyte sedimentation rate (ESR), and general health (GH), both scored 1-100 (higher scores indicate higher disease activity). DAS28 was calculated according to the following formula: DAS28 equals (=) \\[0.56 multiplied by (\\*) the square root (√) of TJC\\] plus (+) \\[0.28 \\* √ of SJC\\] + (0.70 \\* the natural logarithm (ln) ESR in millimeters per hour (mm/h)\\] + \\[0.014 \\* GH in mm visual analogue assessment (VAS)\\]. A negative change from randomization indicated improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"0.83"},{"groupId":"OG001","value":"-0.16","spread":"1.13"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With DAS28 Remission at Week 24","description":"The DAS28 is a combined index for measuring disease activity in RA. The index includes SJC and TJC, both scored 0-28 (higher scores indicate higher disease activity, as well as APR determined as ESR, and GH, both scored 1-100 (higher scores indicate higher disease activity). DAS28 was calculated according to the following formula: DAS28 = 0.56 \\* √ of TJC + 0.28 \\* √ of SJC + 0.70 \\* ln ESR mm/hr + 0.014 \\* GH in mm VAS. DAS28 \\< 2.6 = remission.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.25","spread":null},{"groupId":"OG001","value":"87.50","spread":null}]}]}]},{"type":"SECONDARY","title":"vPercentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Week 24","description":"The CDAI is a combined index for measuring disease activity in RA. CDAI is the sum of TJC and SJC, both scored 0-28 (higher scores indicate higher disease activity), as well as patient global assessment (PGA) and evaluator global assessment (EGA) of disease activity, both scored 0 to 10 centimeter (cm) as assessed by VAS. CDAI was calculated according to the following formula: CDAI = SJC + TJC + PGA + EGA. CDAI \\< 2.8 = remission.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.38","spread":null},{"groupId":"OG001","value":"53.13","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission at Week 24","description":"The SDAI is a combined index for measuring disease activity in RA. SDAI is the sum of TJC and SJC, both scored 0-28 (higher scores indicate higher disease activity), PGA and EGA of disease activity, both scored 0 to 10 cm as assessed by VAS, and C-reactive protein level (CRP) in milligrams per deciliter (mg/dL) where normal \\< 1 mg/dL. CDAI was calculated according to the following formula: SDAI = TJC + SJC + PGA + EGA + CRP. SDAI \\< 3.3 = remission.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.63","spread":null},{"groupId":"OG001","value":"53.13","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5) Remission at Week 24","description":"The RADAI-5 is a combined index for measuring disease activity in RA. RADAI-5 is comprised of the following 5 questions: how active was your arthritis the last 6 months? (0 = completely inactive to 10 = extremely active); how active is your arthritis today with respect to joint tenderness and swelling? (0 = completely inactive to 10 = extremely active); how severe is your arthritis pain today? (0 = no pain to 10 = unbearable pain); how would you describe your general health today? (0 = very good to 10 = very bad); and did you experience joint (hand) stiffness on awakening yesterday morning? If yes, how long did this stiffness last? (0 = no stiffness to 10 = stiffness the whole day). RADAI was calculated according to the following formula: \\[question (Q) 1 + Q2 + Q3 + Q4 + Q5\\]/5. RADAI-5 from 0-1.4 = remission.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.26","spread":null},{"groupId":"OG001","value":"54.55","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Week 12 (Randomization) to Week 24 in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score","description":"HAQ-DI scores were obtained by scoring participants' responses to a 20-item questionnaire. HAQ-DQ evaluated 8 domains of health: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities from a range of 0 (without any difficulty) to 3 (unable to do). The sum of scores was divided by the number of domains for a total score of 0 (best) to 3 (worst). A negative change from randomization indicated improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.28"},{"groupId":"OG001","value":"-0.06","spread":"0.40"}]}]}]},{"type":"SECONDARY","title":"Change From Week 12 (Randomization) to Week 24 in Short Form-36 Health Survey (SF-36) Score","description":"SF-36 scores were obtained by scoring participants' responses to a 36-item questionnaire. SF-36 evaluated 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health from a range of 1 (better) to 5 (worst). The score for each section was an average of the individual question scores, which were scaled 0-100 (100=highest level of functioning). These 8 aspects were summarized as physical and mental component scores. A negative change from randomization indicated improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":"10.48"},{"groupId":"OG001","value":"0.75","spread":"10.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.41","spread":"9.24"},{"groupId":"OG001","value":"-1.69","spread":"9.20"}]}]}]},{"type":"SECONDARY","title":"Change From Week 12 (Randomization) to Week 24 in Visual Analog Scales (VAS) Scores","description":"VAS scores were obtained by scoring participants' disease activity as assessed on a 0-100 millimeter (mm) horizontal visual scale. The left-hand extreme of the line = 0 mm (no disease activity = symptom-free and no arthritis symptoms), and the right-hand extreme of the line = 100 mm (maximum disease activity). A negative change from randomization indicated improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.91","spread":"17.16"},{"groupId":"OG001","value":"-1.88","spread":"17.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.09","spread":"18.48"},{"groupId":"OG001","value":"-2.88","spread":"22.04"}]}]}]},{"type":"SECONDARY","title":"Participant Satisfaction With Treatment as Assessed by Treatment Satisfaction Questionnaire for Medication (TSQM) Score","description":"TSQM scores were obtained by scoring participants' responses to a 14-item questionnaire. TSQM evaluated 4 aspects of treatment satisfaction: effectiveness, side effects, convenience, and global satisfaction from a range of 0 to 100 percent (%), with 100% being the best possible result.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.41","spread":"34.85"},{"groupId":"OG001","value":"82.49","spread":"24.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.15","spread":"19.16"},{"groupId":"OG001","value":"94.89","spread":"14.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.48","spread":"21.97"},{"groupId":"OG001","value":"86.03","spread":"15.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.64","spread":"21.09"},{"groupId":"OG001","value":"86.36","spread":"13.53"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":32},"commonTop":["Alanine aminotransferase increased","Nausea","Leukopenia","Aspartate aminotransferase increased","Nasopharyngitis"]}}}